Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Silo Pharma Inc
Healthcare
P/NCAV
0.9x
Ticker
SILO
Exchange
NASDAQ
Country
United States
Close
1.78 $
Mkt Cap
5.5M $
EV
2.0M $
NCAV Burn Rate
40.5%
Current Ratio
9.9
Debt/Equity
0.0
EV/REV
27.16x
EV/EBIT
-0.5x
EV/FCF
-0.6x
Dilution
13.2% p.A
Total Net Income
-10.3M $
Cheapness
96.0%
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average